Studies have examined the effects of varlitinib, an FDA-approved EGFR/HER2 inhibitor, on various cancers, including gastric, pancreatic, colorectal, and breast cancers (Dokduang et al., 2020). This evidence concerns the gene EGFR and breast carcinoma.